Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
Virginia Liberini(University of Turin), Désirèe Deandreis, Simone Ribero, Marco Rubatto(University of Turin), Riccardo Mimmo(University of Turin), Vincenzo Arena(Università Cattolica del Sacro Cuore), Giulia Polverari(University of Turin), Pietro Quaglino(Department of Medical Sciences), Paolo Fava, Francesco Ceci(University of Turin), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Adriana Lesca(University of Turin), Marilena Bellò, Luca Tonella(University of Turin)
Cited by 4
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
|New England Journal of Medicine|2013|825
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
|JAMA Dermatology|2015|452